Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. by Reddy, J. K. & Qureshi, S. A.
Br. J. Cancer (1979) 40, 476
TUMORIGENICITY OF THE HYPOLIPIDAEMIC PEROXISOME
PROLIFERATOR ETHYL-a-P-CHLOROPHENOXYISOBUTYRATE
(CLOFIBRATE) IN RATS
J. K. IREDDY AND S. A. QURESHI
Fronm2 the Department ofPathology, Northwestern University illedical School, Chicago, Illinois, U.S.A.
Received 9 April 1979 Acceptecl 10 -May 1979
Summary.-Ethyl-a-p-chlorophenoxyisobutyrate (clofibrate), ahypolipidaemic drug
which induces hepatomegaly and proliferation of peroxisomes in liver cells of rats
and mice, was fed to 15 male F344 rats at a dietary concentration of0.5%o (v/w) for up
to 28 months. Hepatocellular carcinomas developed in 10/11 (91 ,h) rats killed between
24 and 28 months. Other tumours included carcinoma of the pancreas (2 rats),
leiomyoma of the small intestine (1 rat) and a large dermatofibrosarcoma (1 rat).
Clofibrate is the third hypolipidaemic peroxisome proliferator demonstrated to be
hepatocarcinogenic in rats. These studies suggest that hypolipidaemic agents which
are capable of producing a sustained hepatomegalic and peroxisome-proliferative
effect also induce liver tumours.
ETHYL o-p-chlorophenoxyisobutyrate
(clofibrate, Fig. 1), which modifies lipid
metabolism (Thorp, 1962; Thorp & War-
ing, 1962), is widely used in the treatment
of hyperlipidaemia in an effort to prevent
ischaemic heart disease (Yeshurun &
Gotto, 1976; Lees & Lees, 1976; Carlson
et al., 1977). Clofibrate induces the pro-
liferation of peroxisomes in liver cells in
rats and mice, and this effect is sustained
as long as the compound is administered
(Hess et al., 1965; Svoboda & Azarnoff,
1966; Reddy et al., 1969). Since hypo-
lipidaemic drugs such as clofibrate are
being administered clinically for long
periods (Finkel, 1977), it is essential to
delineate the long-term biological effects
of these agents. Previous studies from this
laboratory have shown that nafenopin
(2 -methyl - 2 - [p - (1,2,3,4 - tetrahydro - 1 -
CH3
0- C -COOC2H5
CH3
Fin. 1. Structure of clofibrate (ethyl (x-p-
cilloropllenoxyyisobutyrate).
naphthyl) phenoxy] propionic acid=
Su-13,437) and Wy-14,643 ([4-chloro-6-
(2,3 -xylidino) - 2 -pyrimidinylthio) - acetic
acid), two structurally unrelated hypo-
lipidaemic peroxisome proliferators, in-
duce hepatocellular carcinomas in rats and
mice (Reddy et al., 1976, 1979; Reddy &
Rao, 1977). We now report the develop-
ment oftumours in male F344 rats treated
chronically with clofibrate.
MATERIALS AND METHODS
Male F344 rats, weighing 84-100 g, were
obtained from ARS Sprague-Dawley, Madi-
son, WAisconsin, and were housed in individual
cages. Fifteen rats were fed clofibrate
(Atromid-S'; Ayerst Laboratories, NewYork,
N.Y.) at a concentration of0.5o% (v/w) in the
ground rat chowA for up to 28 months. Control
rats were fed the same diet without the drug.
Complete necropsies (wi-ith the exception of
brain) were performed on all animnals; tissues
from selected organs w7ere processed for light
microscopy after fixing in neutral buffered
formalin. Sections, 4-6 jrm thick, woere
stained routinely with haematoxylin and
cosin. The sections of the pancreatic tumours
were also stained with mucicarmine, Fontana
and Grimelius stains. Forelectron microscopy,
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TABLE.-Incidence of tumours in male F344 ratsfed clofibrate
Animals Animals wTith additional tumourst
witlh
No. animals lhepato- Pancreatic Dermato-
_______A _ cellular acinar Leiomyoma fibro-
Group* At start Effectivet carcinomas carcinoma intestine sarcoma
Clofibrate 15 11 10 (91%§) 2 1 1
Control 15 14 0 0 () 0
* Clofibrate -was a(lde(l to powdered clhow at a level of 0o5% (v/w\r) and fed a*d libitum.
The control animals were fed the same chow witlhout the drug, and include animals
serving as long-term conitrols for chrlonic studies with otlher peroxisome proliferators.
t Number of animals killed between 24 and 28 months.
I In relation to the effectiVe number. Significantly different (P < 0-001) from animals
fed control diet, as dcetermine(I by x2 test -with 1 degree of fi-eedom.
§ Occurring concurrently in animals writh liv-er tumours.
samples of liver and liver tumours were fixed
in cold 255% glutaraldehyde in 01M caco-
dylate buffer, pH 7 4, for 30-60 min and
then post-fixed for 1 h in 1% OS04 in 0d1M
S-collidine buffer, pH 7-4. After fixation, the
tissues were dehydrated in ethanol and pro-
cessed as described previously (Reddy et al.,
1974b). For cytochemnical localization of
peroxisome catalase, selected samples of liver
and liver tumours w-ere processed as described
by Novikoff & Goldfischer (1969).
Fic-. 3. Hepatocellular carcinoma meta-
static in lung. H. & E. x 11 2.
FIG. 2. Hepatoceliluar (ai-ciiIoma -with
trabecular patterii from a male i-at fed
clofibrate (0-5°,) for 28 mointlhs. H. & E.
x 85.
RESULTS
Of the 15 rats fed clofibrate, 1 was
killed at 13 months, and 3 more between
17 andI 21 months. The markedly enlarged
32
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Fmc. 4. Electron micrograph revealing portions of ttumour cells fiorn clofibiate-indctivedI liepatocellular
carcinoma. x 12,5(-)O.
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-FIG. 5. Pancreatic carcinoma with inv-asion
of the musctlar w-all of the stomach1.
H.&E. x110.
livers ofthese animals displayed no grosslv
visible lesions, but on microscopic exam-
ination revealed an occasional focuis of
altered liver-cell proliferation. The remain-
ing 11 rats were killed between 24 and 28
months. As seen firom the data in the
Table, the administration of clofibrate in
the diet at, the 0-530 level produceed one
or more liver tumours in 10/11 animals.
These liver tumours meastured 0-3-4 Ciem
in diameter. Histologically, the liver
tumours in these 10 animals fed clofibrate
were well to moderately differentiated
hepatocellular carcinomas (Fig. 2). In one
animal, a few nodules < 3 mm in size were
noted which exhibited the histological
FIG. 6. Higher magnification of a portion of
pancreatic carcinoma revealing acinar
patteioin. H. & E. X 245.
feature ofhyperplastic nodules. Five ofthe
animals with hepatocellular carcinomas
showed pulmonary metastases (Fig. 3).
The primary hepatocellular carcinomas
varied in their ultrastructural differentia-
tion, but many tumour cells contained
prominent peroxisomes (Fig. 4).
Among the other tumours found in
clofibrate-fed animals were pancreatic
acinar carcinoma (2 rats), leiomyoma of
the ileuim (1 rat) and dermatofibrosarcoma
(2 rats). The 2 pancreatic acinar carcino-
mas (Figs. 5 and 6) measured 1-5 and
2*0 cm in diameter respectively, and
invaded the greater curvature of t,he
stomach in both rats. One of these
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tumours metastasized to the liver. The
leiomyoma ofthe ileum (8 mm in diameter)
and the dermatofibrosarcoma of the
skin (6 cm in diameter) were well
differentiated.
DISCUSSION
The relationship of hyperlipidaemia to
prevalence, incidence and mortality from
ischaemic heart disease has been well
established (Stamler et al., 1960; Kannel
et al., 1971). The results of the WHO-
sponsored clinical trial of the effects of
lowering blood cholesterol by therapeutic
intervention with clofibrate in the preven-
tion of ischaemic heart disease clearly
demonstrate that reduction of serum
cholesterol concentrations is relevant to
the prevention of coronary heart disease
(Committee of Principal Investigators,
1978). Despite a significant reduction in
the incidence of ischaemic heart disease
in this study, there were, however, sig-
nificantly more deaths from all causes,
including malignant neoplasms, in the
clofibrate group than in the high-choles-
terol control group (ibid). It is not clear
whether the increased incidence of malig-
nant neoplasms, particularly in the gastro-
intestinal tract and pancreas, is due to the
carcinogenic effect of clofibrate or is
secondary to mobilization of cholesterol
from body pools, leading to increased
levels of faecal sterols and bile acids
(Oliver, 1978) or due to some other
mechanism. Secondary bile acids appear
to enhance carcinogenesis in rat colon
(Reddy et al., 1974). The hypocholesterol-
aemic agents cholestyramine and candicin
have been shown to promote the develop-
ment of intestinal tumours in rats by
altering the faecal bile acids and choles-
terol (Nigro et al., 1977). Whatever may
be the mechanism of increased incidence
of tumours, either in clofibrate-treated
individuals in the WHO-sponsored study
cited above, or in 2 other major primary
prevention trials in which dietary means
for the reduction ofserum cholesterol were
used (Dayton et al., 1969; Miettinen et al.,
1972), it appears necessary to demonstrate
long-term safety for both new and already
marketed hypolipidaemic drugs (Finkel,
1977) if these drugs are to be indicated
for the treatment ofhypertriglyceridaemia
refractory to dietary management (Lees,
1979).
The results of the present study demon-
strate that dietary exposure to clofibrate
produced hepatocellular tumours in male
F344 rats. Although the number of
animals used in these experiments is small,
the liver-tumour incidence in clofibrate-
fed animals, according to x2 analysis, is
significantly different from that in controls
(P < 0-001). In addition, pancreatic acinar
carcinomas developed in 2 rats, leiomyoma
of the ileum in 1 rat, and dermatofibro-
sarcoma in 1 rat. Itis questionable whether
the solitaryleiomyoma ofthe ileum andthe
large dermatofibrosarcoma are induced by
clofibrate, because aged F344 rats occa-
sionally develop spontaneous subcuta-
neous fibromas and fibrosarcomas (Sass
et al., 1975). The pancreatic acinar cell
carcinomas in 2 rats may, however, be
attributable to clofibrate since spontane-
ously occurring malignant exocrine pan-
creatic neoplasms have not been found in
any F344 rats during the past 10 years in
our laboratory. In an earlier study, 20%
(3/15) of F344 rats developed pancreatic
acinar-cell neoplasms when fed nafenopin,
a potent hypolipidaemic peroxisome pro-
liferator which is structurally related to
clofibrate (Reddy & Rao, 1977), suggesting
that these hypolipidaemic agents also
exert a carcinogenic effect in other organs
besides the liver.
Little is known of the mechanism by
wvhich clofibrate exerts its effect in the
initiation or promotion of liver tumour
(Reddy & Rao, 1978). This is now the
third hypolipidaemic hepatic-peroxisome
proliferator (Reddy & Krishnakantha,
1975), shown to be carcinogenic in rats.
The possible relationship of mitogenic
effect, persistent peroxisome proliferation
annd hepatomegaly to hepatocarcinogeni-
city has been considered (Reddy et al.,
1976, 1979). Possible direct interactions
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of hypolipidaemic agents which induce
hepatic peroxisome proliferation with cel-
lular DNA have recently been examined,
using both prokaryotic and eukaryotic cell
in vitro assay systems. None of the drugs
studied (including clofibrate, Wy-14,643
and nafenopin, which have been demon-
strated to be hepatocarcinogenic) were
mutagenic (Warren, J. R., unpublished)
in the AmesSalmonella/microsome reverse-
mutation assay (McCann et al., 1975). In
addition, these hypolipidaemic agents,
added without or with a liver S-9 meta-
bolic-activation system to in vitro cultures
of proliferating lymphocytes (Warren,
1978), failed to inhibit DNA replication
irreversibly (Warren, J. R., unpublished).
It appears therefore that neither the
hypolipidaemic agents nor their metabo-
lites are capable of interacting directly
with cellular DNA. However, further
experimental data, such as information
on the covalent binding of these agents
with liver macromolecules and the use of
other biologicalsystemsfor carcinogenicity
assay, are required to explain this diver-
gence between in vitro and in vivo findings.
The possibility that the hypolipidaemic
compounds induce hepatocellular car-
cinomas in rats and mice via a non-genetic
mechanism similar to that advanced for
saccharin (Ashby et al., 1978) cannot be
ruled out.
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